News from kazia therapeutics ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 09, 2020, 10:30 ET Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data...


Nov 17, 2020, 17:47 ET Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a summary of new...


Oct 16, 2020, 10:30 ET Kazia Executes Agreement To Commence GBM Agile Pivotal Study

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has...


Aug 23, 2020, 21:03 ET US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United...


Aug 20, 2020, 10:30 ET US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United...


Aug 07, 2020, 10:30 ET US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United...


Jun 22, 2020, 10:30 ET Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations...


Jun 01, 2020, 10:30 ET Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation...


Dec 11, 2019, 10:00 ET Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead...


Sep 13, 2019, 08:00 ET Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner ...


Sep 12, 2019, 09:10 ET St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude...


Jul 22, 2019, 09:00 ET Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan ...


Mar 25, 2019, 01:09 ET Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study...